Skip to search formSkip to main contentSkip to account menu

Relugolix

Known as: Urea, N-(4-(1-((2,6-difluorophenyl)methyl)-5-((dimethylamino)methyl)-1,2,3,4-tetrahydro-3-(6-methoxy-3-pyridazinyl)-2,4-dioxothieno(2,3-d)pyrimidin-6-yl)phenyl)-N'-methoxy- 
National Institutes of Health

Related topics

Related topics

1 relation

Narrower (1)

TAK 385

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2020
Review
2020
Relugolix for the treatment of uterine fibroids
ABSTRACT Introduction Uterine fibroids (UF) are benign tumors common in premenopausal women, with strong impact on the health… 
2020
2020
HERO phase III trial: Results comparing relugolix, an oral GnRH receptor antagonist, versus leuprolide acetate for advanced prostate cancer.
5602Background: LHRH agonists are the mainstay for medical castration in advanced prostate cancer; however, they cause an initial… 
2020
2020
Phase 3 HERO Trial Finds Relugolix to Be Superior to Leuprolide in Prostate Cancer.
Results from the phase 3 HERO trial(NCT03085095), presented during the 2020 American Society of Clinical Oncology Virtual… 
2020
2020
Relugolix Combination Therapy Reduced Uterine Fibroid-Associated Pain in Two Phase 3 LIBERTY Studies [32B]
2020
2020
Bone Mineral Density Assessment With Relugolix Combination Therapy
2019
2019
Relugolix: New 0ral Gonadotropin-Releasing Hormone (GnRH) Antagonist
With the recent development of Gonadotropin-Releasing Hormone (GnRH) analogs, physicians have manipulated gonadotropin secretion… 
2019
2019
Relugolix. GnRH (LHRH) receptor antagonist, Treatment of uterine fibroids, Treatment of endometriosis-related pain, Treatment of prostate cancer
Review
2018
Review
2018
New Horizons in Fibroid Management
Purpose of ReviewReview of the latest advances in the treatment of uterine fibroids. Addressing conservative management, medical… 
2017
2017
Phase 2 Study of Relugolix vs Placebo in Heavy Menstrual Bleeding Associated With Uterine Fibroids [17H]
INTRODUCTION:Relugolix is a potent nonpeptide gonadotropin-releasing hormone receptor antagonist. This dose-finding study… 
2017
2017
Relugolix, an oral gonadotropin-releasing hormone (GnRH) receptor antagonist, in women with endometriosis (EM)-associated pain: Phase 2 safety and efficacy 24-week results
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)